Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti –tuberculosis therapy
 Kuteesa R Bisaso^{1}Email author,
 Joel S Owen^{2},
 Francis W Ojara^{1},
 Proscovia M Namuwenge^{3},
 Apollo Mugisha^{4},
 Lawrence Mbuagbaw^{5},
 Livingstone S Luboobi^{6} and
 Jackson K Mukonzo^{1, 3, 7}
DOI: 10.1186/s4020301400039
© Bisaso et al.; licensee Springer. 2014
Received: 26 March 2014
Accepted: 3 September 2014
Published: 16 September 2014
The Erratum to this article has been published in In Silico Pharmacology 2015 3:2
Abstract
Purpose
Plasma albumin, a biomarker for hepatic function, is reported to correspondingly decrease in concentration as disease severity increases in chronic infections including HIV and TB. Our objective was to develop a semimechanistic disease progression model to quantify plasma albumin concentration changes during TB and HIV therapy and identify the associated covariate factors.
Methods
Plasma albumin concentration data was collected at specified times for 3 months from 262 HIV participants receiving efavirenz based anti retroviral therapy. Of these, 158 were TB coinfected and on Rifampicin based anti –tuberculosis cotreatment. An indirect response model with zero order albumin production and first order elimination was developed in NONMEM version 7.2 to describe our data. Genotype (CYP2B6*6 and 11, CYP3A5, ABCB1c.3435C>T and ABCB1rs), TB disease status, baseline age, body weight, plasma creatinine, alanine transaminase enzyme and CD4^{+} count were the potential model covariates tested.
Results
The proposed model successfully described plasma albumin concentration changes in the study population. There was a 10.9% and 48.6% increase in albumin production rates in HIV only and TB coinfected participants respectively. Participants coinfected with TB showed a 44.2% lower baseline albumin secretion rate than those without TB while ABCB1c.3435C>T mutation was associated with a 16% higher steady state albumin secretion rate following treatment.
Conclusion
A semimechanistic model describes plasma albumin concentration changes in HIV patients on ART. Further work is required to establish the utility of the model in monitoring disease progression and predicting prognosis in HIV and TB coinfected patients in absence of or during treatment.
Keywords
NONMEM Disease progression modeling Semimechanistic model Mathematical model Albumin Tuberculosis HIV Anti Retroviral therapy Efavirenz Rifampicin1 Background
In humans, albumin is the most abundant plasma protein (5560% of plasma protein) having a normal plasma concentration of 3.55 g/dl (Bircher et al. [1991]). It is exclusively synthesized in the liver. In normal adults, albumin is synthesized and released at a zeroorder rate of 157–230 mg per kilogram body weight per day into an exchangeable pool of 3.55 grams per kilogram body weight. Approximately 38–45% of albumin is intravascular (Nicholson et al. [2000]). Albumin has a half life of 15–20 days (Nicholson et al. [2000], Beeken et al. [1962]) and elimination mainly occurs in the muscles, skin and kidney (6080%) and the liver and intestinal tract (10% each) (Tavill [1972]).
Among other functions, albumin binds ligands and transports endogenous and exogenous substances, including several drugs in blood (Tavill [1972]). Increase in plasma albumin is associated with significant reduction in intracellular penetration and effectiveness of highly bound antiretroviral drugs like efavirenz (Avery et al. [2013], Boffito et al. [2003]).
Reduced plasma albumin concentrations have been reported in states of chronic infection such as TB, HIV, Hep B and C (Olawumi and Olatunji [2006], Akinpelu et al. [2012], Zia and Shankar [2012]) and as a result, there are suggestions for its use as a prognostic marker in pretreated HIV and TB patients (Feldman et al. [2003], Graham et al. [2007], Sudfeld et al. [2013], AlvarezUria et al. [2013]). Increased catabolism of albumin due to inflammation, worsening of nutritional status as well as a direct degenerative effect on the liver are reported as the probable causes of reduction of plasma albumin in states of chronic infection (Bircher et al. [1991], Kaysen et al. [2002]). Owing to simplicity in terms quantification and low cost of plasma albumin determination, it could substitute CD4+ and viral load tests (Graham et al. [2007], Kannangai et al. [2008]) as a prognostic marker during care for HIV and co morbidities such as TB.
A number of modeling techniques have shown robustness and have been applied in prediction of drug concentrations, pharmacodynamic outcomes and disease progression using biomarkers. We developed and validated a semimechanistic nonlinear mixed effects model describing changes in plasma albumin concentration in HIV and TB patients. The model was used to study changes in albumin production by the liver and the associated covariate factors.
2 Methods
2.1 Data description
The current clinical study was nested in a PhD project (Mukonzo [2011]) and utilized secondary data. The data consisted of 262 ART naïve HIV patients, 158 of whom were coinfected with tuberculosis. The patients were started on combination ART comprised of Efavirenz, lamivudine and zidovudine. Those with TB coinfection had been started on antiTB treatment (2 months ethambutol/isoniazid/rifampicin/pyrizinamide, followed by 4 months of isoniazid and rifampicin) at least 2 weeks prior to starting ART. Blood samples were collected on days 1, 3, 7, 14, 21, 42, 56, and 84 after ART initiation and serum albumin concentrations measured using Abbott Aeroset Bromocresol Green (BCG) (Abbot, Maidenhead, Berkshire, UK) method. In addition, baseline body weight, age, CYP3A5, CYP2B6*6, CYP2B6*11, ABCB1c.3435C>T and ABCB1 c.4046A>G genotype were determined. The study procedure was approved by The Uganda National Council for Science and Technology. Informed consent was obtained from the participants and the study was carried out according to the provisions of the Declaration of Helsinki. Details on study participants and data collection were previously reported (Mukonzo [2011]). Waiver of consent was obtained from Institutional review board of the School of Biomedical Sciences, Makerere University College of Health Sciences to use the data. Also, the data were analyzed anonymously.
2.2 Model development
At t=0, N= N_{0}.
As t→∞, N=N_{ ss }
At the start of treatment, X is given by X_{0} = Q_{0}/k hence, the important parameters to be estimated are Q_{ 0 }, Q_{ ss }, R and k.
2.3 Data analysis
The model was fitted to the data and parameters estimated in a nonlinear mixed effects (“population”) analysis using NONMEM software version 7.2 (Beal and Sheiner [1980], Boeckmann et al. [1994]). The albumin elimination rate constant K was fixed to the literature value of 0.0336/day corresponding to a half life of 20.6 days. The population model parameter estimates were the fixed effects. Interindividual variability in the parameters was modeled as lognormal distribution. The residual error was modeled as proportional but additive and additive plus proportional error models were also tested. The First Order Conditional Estimation (FOCE) method was used for the estimation.
2.4 Covariate analysis
Stepwise covariate analysis was performed using an automated method implemented in PSN software (Lindbom et al. [2004]). The effects of baseline body weight, TB disease status, CYP3A5, CYP2B6*6, CYP2B6*11, ABCB1c.3435C>T and ABCB1c.4046A>G genotypes on parameters Q_{0}, Q_{SS} and R were analyzed. CD4 count and viral load were analyzed as a time varying covariate on parameters Q_{SS} and R. Each covariateparameter relationship was first tested in a univariate manner. Covariates with one degree of freedom were included in the forward selection (α =0.05) if they reduced the OFV by at least 3.84, corresponding to a pvalue of <0.05, for a χ^{2} distribution. The full covariate model was reached when the addition of further covariateparameter relationships did not decrease the OFV to the specified criteria. The covariateparameter relationships were reexamined in the backward deletion step in a manner similar to the forward inclusion step but reversed and with stricter criteria, corresponding to a significance level of α = 0.01 (ΔOFV=6.63 for one less parameter). In addition, the improvement of the fit in the covariate model was also evaluated from the change in the interindividual variability, residual variability and basic goodnessoffit plots (weighted residuals versus predicted concentrations and time, Population predictions versus observed concentrations and time). The final model was used to estimate the parameters.
2.5 Model evaluation
The dataset was randomly split into two. The larger dataset of 174 individuals (approximately two thirds of the whole dataset) was used for model building and bootstrap validation. A nonparametric bootstrap analysis was performed as an internal model evaluation technique. One thousand bootstrap data sets were created from the model development data set and the developed model was fit to each bootstrap data set. The percentage of runs that minimized successfully and estimated the covariance matrix, together with summary statistics (n, mean, median, and standard deviation, minimum, maximum) for the distribution of each model parameter were obtained to determine bias in any parameter. The final model parameter estimates were compared to the median and the percentile 95% confidence intervals (CI) of the nonparametric bootstrap replicates of the final model.
A visual predictive check (VPC) was performed using the final covariate model to evaluate correspondence between prediction corrected measurements and the model. The distribution (median, 5^{th} and 95^{th} percentiles) of the observed albumin concentrations was calculated. The final covariate model and its parameter estimates were used to simulate 1000 new datasets and used to calculate 95% Confidence Intervals for the above mentioned median and percentiles. The median and the percentiles of the measured data were plotted together with the confidence intervals from the model. The VPC was stratified on TB disease status and ABCB1c.3435C>T genotype.
The final model was applied to the validation data set by fixing the final parameter estimates of the model obtained above as the initial parameter values for the validation model and setting MAXEVAL=0 in the $ESTIMATION step, so as to generate predicted concentrations at each time point using the validation dataset of 88 individuals.
The root mean prediction error (imprecision) and the mean percentage prediction error (bias) were obtained according to the method proposed by Sheiner and Beal ([1981]).
3 Results
Demographic characteristics of the study populations
HIV patients receiving HAART (n=262)  

ALL  HIV + TB (n=158)  HIV only (n=104)  
Female (% age)  52.9  49.5 (n=74)  61.5 (n =64) 
Weight/kg  51 (47 – 58)  50.0 (45.0 – 53.0)  55.0 (50.0 – 60.0) 
Age/years  33 (29 – 39)  31 (28 – 37)  37 (31 – 42) 
CD4 cell count/ml  97 (40 – 179)  57 (21 – 137)  147 (89 – 207) 
CD4 cells/ml at 12 weeks  216 (112 – 291)  194 (93 – 277)  247 (167 – 319) 
ALT/Ul^{−1}  18.0 (12 – 28.5)  23.9 (13.6 – 32.6)  14.0 (11 – 21) 
ALB/gdl^{−1}  3.02 (2.35 – 3.85)  2.57 (2.13 – 2.97)  3.91 (3.38 – 4.31) 
ABCB1 3435CC  205  119  86 
ABCB1 3435CT  56  38  18 
ABCB1 3435TT  1  1  0 
CYP2B6*6 (*1/*1)  116  81  35 
CYP2B6*6 (*1/*6)  119  64  55 
CYP2B6*6 (*6/*6)  27  13  14 
CYP3A5 (*0/*0)  59  33  26 
CYP3A5 (*0/*1)  130  86  44 
CYP3A5 (*1/*1)  73  39  34 
The random effects on parameters Q_{ss} and R had high shrinkage (>40%) and had a very low variability of less than 10^{−6} and were therefore dropped from the model.
Population disease progression parameter estimates for albumin dynamics in TBHIV patients (base model)
Parameter  HIV only  Description  

Mean  RSE (%)  
Q_{0} (g/dl/day)  0.1008  3  Baseline albumin secretion rate 
Q_{ss} (g/dl/day)  0.1344  10  Steady state albumin secretion rate 
R (1/day)  0.0096  34  Rate of change from Q_{0} to Q_{ss} 
K (1/day)  0.0336  FIX  Elimination rate constant for albumin 
IIV_Q_{0} (%CV)  25.1  8  Interindividual variability in baseline albumin secretion rate 
Residual error (proportional) (%CV)  18.4  5  Variability in the residual error 
Parameter estimates of full covariate model
Parameter  Original dataset  Bootstrap datasets  

Mean  *RSE (%)  Median  95% CI lower limit  95% CI upper limit  
Q_{0} (g/dl/day)  0.0864  2  0.0864  0.084  0.0912 
Q_{0} (HIV only)  0.1248  14  0.1248  0.108  0.1296 
Q_{0} (ABCB1 mutation)  0.1008  34  0.1008  0.0864  0.1056 
Q_{ss} (g/dl/day)  0.1464  16  0.1440  0.1176  0.3288 
R (1/day)  0.0072  45  0.0072  0.001927  0.0144 
K (1/day)  0.0336  FIX  0.0336  NA  NA 
Random effects parameters for both HIV only and TBHIV  
IIV_Q_{0} (%CV)  15.0  14  14.6  11.1  19.3 
Residual error (proportional) (%CV)  18.2  5  18.1  16.8  19.8 
Stability of the model was determined by use of nonparametric bootstrap technique using PsN. Of the 1000 bootstrap replicates, 950 minimized successfully were used to generate medians of parameters and percentile 95% confidence interval. As shown in Table 3, the mean parameter estimates obtained by fitting the final model to the data were similar to the median of the 950 bootstrap replicates and were contained within the 95% confidence interval, suggesting a high accuracy of NONMEM parameter estimates. The NONMEM parameter estimates also had moderate precision with relative standard errors of less than 50% for mean parameters and the random effects.
4 Discussion
Plasma albumin concentration is a function of its rate of synthesis, distribution and degradation. Hypoalbuminemia is a more common occurrence than hyperalbuminemia. Rapid changes in plasma albumin (occurring within hours) are most likely due to changes in elimination rate (fractional catabolic rate) or distribution of albumin as a result of either increased plasma water content or net movement into the interstitial space. However, because of its long half life, a sustained fall in albumin suggests clinically significant deterioration in its rate of synthesis by the liver (Kaysen et al. [2002], Bircher et al. [1991]). The present study utilized albumin concentration data collected over three months, therefore the model predictions are representative of chronic changes in albumin concentration.
The present model adequately describes the observed changes in albumin concentration and predicts population observation with minimum bias and error. The mean baseline albumin concentrations calculated from the estimated model parameters are similar to those observed. The baseline albumin secretion rate was significantly lower in patients coinfected with TB and HIV than in those with HIV only.
Individuals with ABCB1c.3435CC genotype had a 16% lower value of Q_{0} than those with ABCB1c.3435CT and ABCB1c.3435TT implying that presence of a mutation is associated with higher albumin secretion rates before treatment with ART. It is not immediately clear why this is the case since this single nucleotide polymorphism (SNP) has also been associated with predisposition to ART and rifampicin based antiTB Drug Induced Liver Injury (DILI) through a possible low transport activity (Yimer et al. [2011], Thiebaut et al. [1987]).
Notably however is that when modeled as time varying covariates, neither CD4 count nor viral load had significant effects (p<0.05) on the model quantitative measures of disease progression and prognosis (R or Q_{ss}). This is possibly explained by the fact that albumin concentrations improve secondary to overall health improvement upon initiation of HAART and antiTB treatment. This therefore implies that although albumin may be a cheap and suitable prognostic marker for monitoring HIV disease, comorbidities and ART, there is need for validation studies.
Disease progression modeling, a technique that was employed by the current study remains one of the most robust ways for prediction of associations and multiple covariate analysis. The model developed in this study is robust and has stable parameter estimates, satisfactorily describes the data and has a high predictive capacity. Nevertheless the model has limitation including the estimation of albumin kinetics using a simple one compartment model rather than the known two compartment kinetics as well as inability to model and estimate the variability. This was because of very sparse data which could not allow estimation of several parameters. We were also unable to model the change in albumin elimination rate partly because of the sparse data but also because our objective was to study the albumin production dynamics. Other limitations included the assumed negligible maturation time of new hepatocytes, as well as lag time between synthesis and secretion of albumin by hepatocytes as compared to the study period of three months.
Notwithstanding the limitations highlighted here, this model had high precision and low bias in prediction thus it can be used to predict plasma albumin concentration in individual patients. It is useful in predicting prognosis (Mehta et al. [2006]) and could be useful in describing pharmacokinetics of albumin bound drugs in these patients. In addition, our model provides a basis for extended models describing treatment effects, comparing different treatment regimens as well as accounting for direct drug toxicity on the liver.
5 Conclusion
In conclusion, the proposed one compartment semimechanistic model described changes in plasma albumin concentration following initiation of HAART in HIV patients with or without TB. Changes in albumin synthesis and secretion could influence changes in plasma albumin concentrations in patients on HAART. ABCB1c.3435C>T genotype and TB disease status are significantly associated with albumin secretion rates before initiation of ART in patients receiving HIV and TB cotreatment. The model could be useful in studying the variation in pharmacokinetic profiles of drugs that are highly protein bound in these patients during different stages of treatment with HAART. More work needs to be done establish the utility of this model in monitoring disease progression and predicting prognosis in HIV and TB patients.
Additional file
Notes
Abbreviations
 ART:

Anti retroviral therapy
 HAART:

Highly active Antiretroviral therapy
 HIV:

Human immunodeficiency virus
 VPC:

Visual predictive check
 SNP:

Single nucleotide polymorphism
 TB:

Tuberculosis
Declarations
Acknowledgements
The collection of the data used in this study was supported by SIDA/SAREC, grant No. SWE 2007–270 Makerere UniversityKarolinska Institutet research collaboration.
Authors’ Affiliations
References
 Akinpelu OO, Aken’ova YA, Ganiyu Arinola O: Levels of immunoglobulin classes are not associated with severity of HIV infection in nigerian patient. World Journal of AIDS 2012, 2: 232–236. 10.4236/wja.2012.23030View ArticleGoogle Scholar
 AlvarezUria G, Midde M, Pakam R, Naik PK: Diagnostic and prognostic value of serum albumin for tuberculosis in HIV infected patients eligible for antiretroviral therapy: datafrom an HIV cohort study in india. Bioimpacts 2013, 3: 123–128.PubMedPubMed CentralGoogle Scholar
 Avery LB, Zarr MA, Bakshi RP, Siliciano RF, Hendrix CW: Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. AIDS Res Hum Retroviruses 2013, 29: 1434–1442. 10.1089/aid.2013.0031View ArticlePubMedPubMed CentralGoogle Scholar
 Beal SL, Sheiner LB: The nonmem system. Amer Statist 1980, 34: 118–119. 10.2307/2684123View ArticleGoogle Scholar
 Boeckmann AJ, Sheiner LB, Beal SL: NONMEM Users Guides, NONMEM Project Group. University of California, San Francisco; 1994.Google Scholar
 Beeken WL, Volwiler W, Goldsworthy PD, Garby LE, Reynolds WE, Stogsdill R, Stemler RS: Studies of I131albumin catabolism and distribution in normal young male adults. J Clin Invest 1962, 41: 1312–1333. 10.1172/JCI104594View ArticlePubMedPubMed CentralGoogle Scholar
 Bircher J, Benhamou JP, Mcintyre N: Oxford Textbook of Clinical Hepatology. Oxford University Press, New York; 1991.Google Scholar
 Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V: Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003, 19: 825–835. 10.1089/088922203769232629View ArticlePubMedGoogle Scholar
 Feldman JG, Gange SJ, Bacchetti P, Cohen M, Young M, Squires KE, Williams C, Goldwasser P, Anastos K: Serum albumin is a powerful predictor of survival among HIV1infected women. J Acquir Immune Defic Syndr 2003, 33: 66–73. 10.1097/0012633420030501000010View ArticlePubMedGoogle Scholar
 Graham SM, Baeten JM, Richardson BA, Wener MH, Lavreys L, Mandaliya K, NdinyaAchola JO, Overbaugh J, Mcclelland RS: A decrease in albumin in early HIV type 1 infection predicts subsequent disease progression. AIDS Res Hum Retroviruses 2007, 23: 1197–1200. 10.1089/aid.2007.0065View ArticlePubMedGoogle Scholar
 Kannangai R, Kandathil AJ, Ebenezer DL, Mathai E, Prakash AJ, Abraham OC, Sudarsanam TD, PULIMOOD SA, Selvakumar R, Job V, Sridharan G: Usefulness of alternate prognostic serum and plasma markers for antiretroviral therapy for human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2008, 15: 154–158. 10.1128/CVI.0019307View ArticlePubMedPubMed CentralGoogle Scholar
 Karlsson MO, Savic RM: Diagnosing model diagnostics. Clin Pharmacol Ther 2007, 82: 17–20. 10.1038/sj.clpt.6100241View ArticlePubMedGoogle Scholar
 Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW: Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 2002, 61: 2240–2249. 10.1046/j.15231755.2002.00076.xView ArticlePubMedGoogle Scholar
 Lindbom L, Ribbing J, Jonsson EN: PerlspeaksNONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004, 75: 85–94. 10.1016/j.cmpb.2003.11.003View ArticlePubMedGoogle Scholar
 Mehta SH, Astemborski J, Sterling TR, Thomas DL, Vlahov D: Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses 2006, 22: 14–21. 10.1089/aid.2006.22.14View ArticlePubMedGoogle Scholar
 Mukonzo JK: Pharmacokinetic aspects of HIV/AIDS, Tuberculosis and Malaria: Emphasis on the Ugandan Population. In Dissertation. Karolinska Institutet, Stockholm Sweden; 2011.Google Scholar
 Murray JD: Mathematical Biology1: An introduction. Springer, New York; 2002.Google Scholar
 Nicholson JP, Wolmarans MR, Park GR: The role of albumin in critical illness. Br J Anaesth 2000, 85: 599–610. 10.1093/bja/85.4.599View ArticlePubMedGoogle Scholar
 Olawumi HO, Olatunji PO: The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients. HIV Med 2006, 7: 351–355. 10.1111/j.14681293.2006.00391.xView ArticlePubMedGoogle Scholar
 Post TM: Disease system analysis: between complexity and (over)simplification. In Dissertation. Leiden University, Leiden Netherlands; 2009.Google Scholar
 Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981, 9: 503–512. 10.1007/BF01060893View ArticlePubMedGoogle Scholar
 Sudfeld CR, Isanaka S, Aboud S, Mugusi FM, Wang M, Chalamilla GE, Fawzi WW: Association of serum albumin concentration with mortality, morbidity, CD4 Tcell reconstitution among tanzanians initiating antiretroviral therapy. J Infect Dis 2013, 207: 1370–1378. 10.1093/infdis/jit027View ArticlePubMedPubMed CentralGoogle Scholar
 Tavill AS: The synthesis and degradation of liverproduced proteins. Gut 1972, 13: 225–241. 10.1136/gut.13.3.225View ArticlePubMedPubMed CentralGoogle Scholar
 THIEBAUT F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrugresistance gene product Pglycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987, 84: 7735–7738. 10.1073/pnas.84.21.7735View ArticlePubMedPubMed CentralGoogle Scholar
 Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E: Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based antiTB drug induced liver injury in TBHIV infected patients. PLoS One 2011, 6: e27810. 10.1371/journal.pone.0027810View ArticlePubMedPubMed CentralGoogle Scholar
 Zia HKHAN, Shankar SWARKE: Effect of antituberculosis drugs on levels of serum proteins in pulmonary tuberculosis patients. International Journal of Pharmaceutical Research & Allied Sciences 2012, 1: 94–100.Google Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.